# A Phase 1 Study of GS101 Injection

> **NCT07411755** · PHASE1 · RECRUITING · sponsor: **Jiangsu Genscend Biopharmaceutical Co., Ltd** · enrollment: 294 (estimated)

## Conditions studied

- Atopic Dermatitis (AD)

## Interventions

- **DRUG:** GS101 injection
- **DRUG:** U.S. commercial Dupixent®
- **DRUG:** CN commercial Dupixent®

## Key facts

- **NCT ID:** NCT07411755
- **Lead sponsor:** Jiangsu Genscend Biopharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07411755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07411755, "A Phase 1 Study of GS101 Injection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07411755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*